- Home
- FBRX vs CLSD Comparison
FBRX vs CLSD Comparison
Compare FBRX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- CLSD
- Stock Information
- Founded
- FBRX N/A
- CLSD 2011
- Country
- FBRX United States
- CLSD United States
- Employees
- FBRX N/A
- CLSD N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- CLSD Health Care
- Exchange
- FBRX Nasdaq
- CLSD Nasdaq
- Market Cap
- FBRX 76.1M
- CLSD 81.2M
- IPO Year
- FBRX N/A
- CLSD 2016
- Fundamental
- Price
- FBRX $10.98
- CLSD $0.95
- Analyst Decision
- FBRX Strong Buy
- CLSD Strong Buy
- Analyst Count
- FBRX 4
- CLSD 6
- Target Price
- FBRX $77.58
- CLSD $5.33
- AVG Volume (30 Days)
- FBRX 27.5K
- CLSD 214.9K
- Earning Date
- FBRX 03-17-2025
- CLSD 03-11-2025
- Dividend Yield
- FBRX N/A
- CLSD N/A
- EPS Growth
- FBRX N/A
- CLSD N/A
- EPS
- FBRX N/A
- CLSD N/A
- Revenue
- FBRX N/A
- CLSD $7,703,000.00
- Revenue This Year
- FBRX N/A
- CLSD N/A
- Revenue Next Year
- FBRX N/A
- CLSD $91.87
- P/E Ratio
- FBRX N/A
- CLSD N/A
- Revenue Growth
- FBRX N/A
- CLSD 248.39
- 52 Week Low
- FBRX $4.11
- CLSD $0.80
- 52 Week High
- FBRX $28.68
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- FBRX 36.53
- CLSD 43.06
- Support Level
- FBRX $9.81
- CLSD $1.00
- Resistance Level
- FBRX $13.13
- CLSD $1.09
- Average True Range (ATR)
- FBRX 1.52
- CLSD 0.07
- MACD
- FBRX -0.08
- CLSD -0.01
- Stochastic Oscillator
- FBRX 18.17
- CLSD 16.30
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.